Drugs / DASH CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05651191 | Oct 2022 → Sep 2024 | B-cell acute lymphoblastic leukemia | Hrain Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DASH CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05651191 ↗ |
| Modality | Cell therapy | “Autologous genetically modified anti-CD19 CAR transduced T cells” NCT05651191 ↗ |
| Target | CD19 | “human CD19 targeted DASH CAR-T Cells injection” NCT05651191 ↗ |